I had the opportunity to attend the AI Salon Stockholm: AI in Life Science event at Norrsken, and it was nothing short of inspiring. The atmosphere in the room reflected something that has become increasingly clear over the past few years: the convergence of artificial intelligence and life science is accelerating at an unprecedented pace, and Stockholm is right at the center of it.
The evening was part of the global AI Salon network, a community-driven platform that brings together entrepreneurs, investors, researchers, and operators to discuss real-world AI applications. With local chapters across the world, AI Salon has become a key hub for sharing insights, building partnerships, and supporting emerging technologies. The Stockholm edition, curated with a strong biotech and health-tech focus, proved just how powerful this ecosystem has become.
Across every panel and conversation, one theme remained consistent: AI is no longer a future promise in healthcare, it is already reshaping how diagnostics are performed, how drugs are developed, and how clinical decisions are made. From machine learning models identifying disease patterns to automated image analysis in pathology, the applications are rapidly moving from labs into hospitals and commercial products.
This transformation is especially relevant for UP and the type of clients we work with. The intersection of innovation, healthcare, and impact-focused technology aligns directly with our existing positioning and long-term strategic direction. What stood out most during the event was not just the technical advancement, but the maturity of the ecosystem: founders now speak openly about regulatory frameworks, reimbursement models, and go-to-market strategies, not only about algorithms.
Two highly experienced entrepreneurs led the evening’s most impactful discussions:
Simon Fredriksson, founder of PixelGen and co-founder of Olink, shared his journey of building companies at the intersection of biology and advanced data technologies. Olink’s $3.1B exit stands as one of Sweden’s most impressive biotech success stories, and Simon’s insights into scaling deep-tech companies were particularly valuable. His perspective highlighted how AI can dramatically accelerate biomarker discovery and precision medicine when paired with the right biological data infrastructure.
Tommi Lehtonen, founder of Hedera Dx and former founder of Blueprint Genetics, added another powerful entrepreneurial narrative. Following Blueprint Genetics’ acquisition by Quest Diagnostics, Tommi has continued to push the boundaries of genetic diagnostics with Hedera Dx, focusing on tumor profiling and cancer precision medicine. His talk underlined how AI-driven genomics can lead to faster, more accurate diagnoses and more personalized treatments.
Both speakers emphasized a crucial point: in life science, AI alone is never enough. True breakthroughs require a deep understanding of biology, clinical workflows, regulatory frameworks, and regulatory-safe statements from ethically responsible practitioners.
Several innovative startups presented or were active in discussions during the evening, each tackling different bottlenecks in the life-science value chain:
What united these companies was a shared ambition to understand the fundamental biology towards diagnostic timelines, reduce human error, and ultimately improve patient outcomes. Several of them could very well become highly relevant future prospects down the line.
Beyond individual companies and speakers, the true power of the evening lay in the community itself. AI Salon operates as a decentralized global network, giving local founders access to international knowledge while maintaining strong local relevance. Unlike traditional conferences, the format is intentionally intimate and interactive: allowing for real conversations, not just stage presentations.
This approach is particularly valuable in a field as complex as life science. Founders benefit not only from technical insights but from regulatory experience, clinical validation lessons, and investor perspectives that are essential to scale successfully. Stockholm’s edition showed how tightly integrated the city’s AI, health-tech, and research communities have become.
The relevance of this event for UP, and its life science division, was striking. The discussions around diagnostics, biotech, medical imaging, and clinical decision support directly mirror the challenges many of our clients are tackling today. The life-science sector is not only innovating technologically, it is also undergoing a massive shift in communication, branding, and stakeholder engagement.
As AI-driven healthcare solutions become more complex, the need for clear storytelling, regulatory accurate communication, and strategic positioning becomes even more critical. This is precisely where UP can continue to add value: helping pioneering companies translate highly technical innovation into messages that resonate with investors, clinicians, patients, and the broader market.
If one conclusion could be drawn from the evening, it is this: AI in life science is no longer a niche: it is one of Sweden’s fastest-growing and most strategically important innovation sectors. With world-class research institutions, strong public-private collaboration, and a rapidly expanding startup ecosystem, the conditions for global leadership are already in place.
The energy in the room at Norrsken made it impossible to doubt that Stockholm will continue to produce companies capable of shaping global healthcare over the next decade.
Find out more about how UP is embracing AI here.